Skip to content

Study Details

Efzofitimod: A Study Drug for People with Pulmonary Sarcoidosis

(IRB#: IRB_00156634)

Pulmonary Sarcoidosis is a disease that most commonly affects the lungs and causes other health conditions that impact a persons quality of life. Efzofitimod is a study drug to help people with this disease. Research is needed to learn the safety and effectiveness of the drug. The information we gain may aid future patients.


  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 18-75 years old
  • Diagnosis of Pulmonary Sarcoidosis
  • Receiving treatment with oral corticosteroids for 3 months or longer and receiving the same dose for 4 weeks or longer
  • Willing to lessen and then stop the dose of oral corticosteroid
  • Willing to use birth control during the study

Exclusion Criteria

  • Treatment with more than 1 oral immunosuppressant therapy (e.g. methotrexate, leflunomide)
  • Major surgery or hospitalization in the past 3 months or scheduled surgery during the study
  • Active, heavy smoker of tobacco/nicotine-containing products (defined as greater than 20 cigarettes/day or e-cigarette equivalent)
  • Active substance abuse or history 12 months before participation
  • Pregnant

Will I be paid for my time?


For more information contact:

Chloe Kirkpatrick


IRB#: IRB_00156634


Department: PULMONARY

Approval Date: 2023-01-11 07:00:00

Specialties: Pulmonary

Last Updated: 6/8/23